| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
This study clarified that the expression of CXCR3A and CXCR3B play an important role in progression and metastasis in renal cell carcinoma (RCC). The ratio of CXCR3A/CXCR3B was significantly higher in patients with metastatic RCC at the time of surgery. The RCC cell line, 786-O, which has a higher ratio of CXCR3A/CXCR3B significantly increased in migration and invasion function by addition of the ligand CXCL10.
Furthermore, the ligands, CXCL9 and CXCL10, might be able to reflect the condition of a disease in metastatic RCC patients who took sunitinib. CXCL9 and CXCL10 show the possibility as a new tumor biomarker, when the patients with metastatic RCC receive the molecular targeted therapy.
|
